{"id":"W4413810049","doi":"10.1016/s2152-2650(25)01688-x","title":"AML-542: GO-First: Real-World Data of Frontline Gemtuzumab Ozogamicin in Intermediate- and Favorable-Risk Patients With AML in a Multicenter Retrospective Chart Review","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Pfizer (Canada)","funders":"","keywords":"Gemtuzumab ozogamicin; Medicine; Chart; Real world evidence; Intensive care medicine; Pediatrics; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009101007,0.0002152577,0.0005251469,0.001714097,0.0003152673,0.001083046,0.0004358721,0.0003504752,0.001720478],"category_scores_gemma":[0.002951727,0.0002461758,0.0004800123,0.002816657,0.0002974663,0.0007323854,0.0004581048,0.0003796094,0.0003339674],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009264788,"about_ca_system_score_gemma":0.001121898,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004360889,"about_ca_topic_score_gemma":0.00589232,"domain_scores_codex":[0.9988396,0.0002219927,0.0002438199,0.000334424,0.0002334299,0.0001268609],"domain_scores_gemma":[0.9962428,0.0006859012,0.002105965,0.0002528432,0.0004095445,0.0003029756],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00107553,0.00006207656,0.9817488,0.0005086674,0.0004214044,0.0006577651,0.0002704905,0.0001083435,0.000840896,0.0002555929,0.004389925,0.009660586],"study_design_scores_gemma":[0.0001530796,0.0001925982,0.980581,0.0002927535,0.0006063114,0.002642159,0.0007521461,0.0003325444,0.0008839598,0.00008806626,0.01344153,0.00003385466],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9567215,0.009736327,0.0005416147,0.0003882393,0.00003755095,0.0002172283,0.0298747,0.00005405769,0.002428703],"genre_scores_gemma":[0.97568,0.002924143,0.0008001127,0.0002589446,0.00004213622,0.000133109,0.0198775,0.00002708368,0.0002569214],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004360889,"threshold_uncertainty_score":0.008670986,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02913672146435998,"score_gpt":0.3539792207891495,"score_spread":0.3248424993247895,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}